Pediazole is a combination of erythromycin ethylsuccinate, USP, and sulfisoxazole acetyl, USP. When reconstituted with water as directed on the label, the granules form a white, strawberry-banana flavor suspension that provides the equivalent of 200 mg erythromycin activity and the equivalent of 600 mg of sulfisoxazole activity per teaspoonful (5 mL).
For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Pediazole, USP, and other antibacterial drugs, Pediazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Pediazole (Erythromycin / Sulfisoxazole)
Otitis Media Prescriptions Differ by Race
Source: Medscape Pediatrics Headlines [2014.11.17]
Racial differences in otitis media care between black and nonblack children suggest that the majority of children in the United States are inappropriately receiving broad-spectrum antibiotics.
Medscape Medical News
Ear Infection (Otitis Media)
Source: MedicineNet Adenoids and Tonsils Specialty [2014.07.11]
Title: Ear Infection (Otitis Media)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/11/2014 12:00:00 AM
Complications of tube insertion in ears not worse for kids with cleft lip/palate
Source: Cleft Palate News From Medical News Today [2014.08.29]
Children with cleft lip and/or palate (CLP) have no worse complications from ventilation tube (VT) insertion in their ears to treat otitis media with effusion (OME, a buildup of fluid in the ear)...
Published Studies Related to Pediazole (Erythromycin / Sulfisoxazole)
Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. [1991.12]
We randomly assigned children with otitis media with effusion to receive either erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for a 2-week period, primarily to determine whether either erythromycin-sulfisoxazole or cefaclor would have greater short term efficacy than that found previously for amoxicillin, and secondarily to supplement earlier data on outcomes in placebo-treated subjects...
[An open randomized trial, Pediazole versus cefaclor in the treatment of acute otitis media in children] [1991.02]
The combination of erythromycin ethylsuccinate and acetyl sulfafuroxazole (Pediazole = ES) is effective against Hemophilus influenzae, including beta-lactamase-producing strains, and against Streptococcus pneumoniae, including macrolide-resistant strains... Clinical results were as follows: failures before or at completion of the course, 5/52 in the ES group versus 13/51 in the cefaclor for the treatment of children with acute otitis media.
[Acute otitis media in children: a randomized and open clinical trial of the efficacy of 2 major antibiotics (erythromycin ethylsuccinate/acetyl sulfafurazole vs amoxicillin/clavulanic acid)] [1990.02]
In a prospective randomized open study, 111 young children with otitis media were orally treated during 10 days with Pediazole (50 mg/kg/day in 3 divided doses) or amoxicillin + clavulanic acid (40 mg/kg/day in 3 or 4 divided doses) for efficacy and safety evaluation... In conclusion, Erythromycin sulfisoxazole combination (Pediazole) fits in with current epidemiological profile of Acute Otitis Media and represents a therapy of choice in this indication.
Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. 
Pneumocystis carinii pneumonitis was effectively prevented in 90% of immunosuppressed rats by the administration of 100 mg of erythromycin and 300 mg/kg/day of sulfisoxazole.The established safety record from three decades of clinical use of this drug combination plus the broad spectrum of coverage for other causes of diffuse pneumonitis such as Chlamydia, Mycoplasma, and Legionella warrant further study of erythromycin-sulfisoxazole in AIDS patients.
Erythromycin-induced immune hemolytic anemia. 
A 3-year-old female receiving Pediazole (erythromycin ethylsuccinate and sulfisoxazole) for tonsillitis and otitis media developed severe hemolytic anemia. No serum drug-dependent antibodies could be demonstrated with an in vitro 'immune-complex' method using Pediazole, pure erythromycin ethylsuccinate or pure sulfisoxazole...
Page last updated: 2014-11-17